Original paper

Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease

Volume: 329, Pages: 1198 - 1209
Published: Jan 1, 2021
Abstract
Nanoparticle drug delivery has many advantages over small molecule therapeutics, including reducing off-target side effects and increasing drug potency. However, many nanoparticles are administered parenterally, which is challenging for chronic diseases such as polycystic kidney disease (PKD), the most common hereditary disease worldwide in which patients need continuous treatment over decades. To address this clinical need, we present the...
Paper Details
Title
Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease
Published Date
Jan 1, 2021
Volume
329
Pages
1198 - 1209
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.